Core Insights - KindlyMD, Inc. has entered into an open credit facility with Two Prime Lending Limited, securing a term loan of $203,017,500 [1] - The financing primarily aims to redeem a $200 million convertible debenture, along with 1.5% interest, with YA II PN, Ltd. [1] Financial Strategy - The loan proceeds will enhance the company's balance sheet while allowing it to preserve its Bitcoin holdings [1] - This move provides flexibility for KindlyMD to pursue its long-term growth strategy [1]

(Primary Standard Industrial Classification Code Number) Israel 2836 Not Applicable As filed with the United States Securities and Exchange Commission on September 22, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scinai Immunotherapeutics Ltd. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Copies of all communications, ...

FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scinai Immunotherapeutics Ltd. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Israel 2836 Not Applicable As filed with the United States Securities and Exchange Commission on September 22, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. Employer Identificatio ...

As filed with the U.S. Securities and Exchange Commission on September 18, 2025. Registration No. 333-290206 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Icon Energy Corp. (Exact name of Registrant as specified in its charter) Republic of the Marshall Islands (State or other jurisdiction of incorporation or organization) 4412 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Empl ...

As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. 333-______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 N2OFF, INC. (Exact name of registrant as specified in its charter) incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer HaPardes 134 (Meshek Sander) Nev ...

As filed with the U.S. Securities and Exchange Commission on June 6, 2025 Registration No. 333-286569 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ Yorkville Acquisition Corp. (Exact name of registrant as specified in its charter) ___________________________________ | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial C ...

Core Viewpoint - Scinai Immunotherapeutics Ltd. has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to sell up to $10 million of its American Depository Shares (ADSs) over a three-year period to support its R&D and CDMO business expansion [1][2][5]. Group 1: SEPA Details - The SEPA allows Scinai to sell ADSs at a 3% discount to the lowest daily volume-weighted average price over three consecutive trading days following an advance notice [3]. - Scinai retains full control over the timing and amount of sales under the SEPA, with no obligation to utilize the full $10 million [4]. - The agreement includes a beneficial ownership cap of 9.99% of Scinai's share capital at any one time, along with other restrictions [2]. Group 2: Use of Proceeds - Proceeds from the potential offering of ADSs under the SEPA will be used to further develop NanoAbs programs, support the CDMO business, and for general corporate purposes including working capital and regulatory matters [5]. Group 3: Company Overview - Scinai Immunotherapeutics is focused on developing inflammation and immunology biological products and offers CDMO services through its Scinai Bioservices unit [1][7]. - The company has a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with significant unmet medical needs [7].

As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. 333-276474 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAVE FOODS, INC. (Exact name of registrant as specified in its charter) (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) VCorp Services, LLC 701 S. Carson Street Suite 200 Carson City, N ...

As filed with the Securities and Exchange Commission on January 11, 2024 Registration No. 333-_______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAVE FOODS, INC. (Exact name of registrant as specified in its charter) Nevada 2000 26-4684680 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the ...

As filed with the Securities and Exchange Commission on October 26, 2023 Registration No. 333-274932 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAVE FOODS, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Delaware 2000 26-4684680 HaPa ...